A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of Osilodrostat (LCI699) in Subjects With Impaired Hepatic Function Compared to Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Pharmacokinetics
- Sponsors Novartis
- 09 Sep 2016 Status changed from recruiting to completed.
- 05 Jun 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.
- 02 Mar 2015 New trial record